Daidone M G, Silvestrini R, Valentinis B, Ferrari L, Bartoli C
Istituto Nazionale Tumori, Milan, Italy.
Int J Cancer. 1991 Feb 1;47(3):380-3. doi: 10.1002/ijc.2910470312.
Changes in the 3H-thymidine labelling index (3H-TdR LI) of primary tumor induced by cytoreductive chemotherapy were evaluated in 26 patients with locally advanced breast cancer subjected to mastectomy after different systemic therapies. A significant reduction of 3H-TdR LI by primary chemotherapy was observed in 11 cases. Changes in cell kinetics were related to the pretreatment proliferative activity: significant increases were observed in 70% of tumors with a very low 3H-TdR LI (less than 25%) and significant decreases in 100% of tumors with a very high 3H-TdR LI (greater than 7.0%). There was no correlation between pretreatment 3H-TdR LI and the objective clinical response, which was conversely related to posttreatment cell kinetics. The 2-year progression rate was lower for patients whose residual tumors after treatment had remained (2/7) or become (1/8) slowly proliferating than for patients whose tumors had remained (5/7) or become (4/4) rapidly proliferating.
在26例局部晚期乳腺癌患者中，评估了不同全身治疗后行乳房切除术的原发肿瘤经减瘤化疗诱导的3H-胸腺嘧啶核苷标记指数（3H-TdR LI）的变化。11例患者经初次化疗后3H-TdR LI显著降低。细胞动力学变化与预处理增殖活性有关：3H-TdR LI非常低（低于25%）的肿瘤中，70%观察到显著增加；3H-TdR LI非常高（大于7.0%）的肿瘤中，100%观察到显著降低。预处理3H-TdR LI与客观临床反应之间无相关性，客观临床反应反而与治疗后细胞动力学相关。治疗后残留肿瘤保持缓慢增殖（2/7）或变为缓慢增殖（1/8）的患者，其2年进展率低于肿瘤保持快速增殖（5/7）或变为快速增殖（4/4）的患者。
